{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T04:04:13Z","timestamp":1745640253339,"version":"3.40.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070120","81600097","82070120"],"award-info":[{"award-number":["82070120","81600097","82070120"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00277-025-06265-6","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T07:45:46Z","timestamp":1740555946000},"page":"1949-1960","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sequential combined bypassing therapy in haemophilia patients with high titer inhibitors: surgical experience"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1567-8100","authenticated-orcid":false,"given":"Bingjie","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8341-7957","authenticated-orcid":false,"given":"Xuewen","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengjuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujun","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guancong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhehuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5259-1429","authenticated-orcid":false,"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7346-7435","authenticated-orcid":false,"given":"Hu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"issue":"1","key":"6265_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","volume":"7","author":"E Berntorp","year":"2021","unstructured":"Berntorp E, Fischer K, Hart DP, Mancuso ME, Stephensen D, Shapiro AD et al (2021) Haemophilia. Nat Rev Dis Primers 7(1):45. https:\/\/doi.org\/10.1038\/s41572-021-00278-x","journal-title":"Nat Rev Dis Primers"},{"issue":"1 Suppl 1","key":"6265_CR2","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1053\/j.seminhematol.2005.11.024","volume":"43","author":"J Ingerslev","year":"2006","unstructured":"Ingerslev J, Hvid I (2006) Surgery in hemophilia. The general view: patient selection, timing, and preoperative assessment. Semin Hematol 43(1 Suppl 1):S23\u2013S26. https:\/\/doi.org\/10.1053\/j.seminhematol.2005.11.024","journal-title":"Semin Hematol"},{"issue":"Suppl 1","key":"6265_CR3","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/j.thromres.2012.08.265","volume":"130","author":"MC Ozelo","year":"2012","unstructured":"Ozelo MC (2012) Surgery in patients with hemophilia: is thromboprophylaxis mandatory? Thromb Res 130(Suppl 1):S23\u2013S26. https:\/\/doi.org\/10.1016\/j.thromres.2012.08.265","journal-title":"Thromb Res"},{"issue":"3","key":"6265_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/17474086.2021.1893689","volume":"14","author":"EC Rodriguez-Merchan","year":"2021","unstructured":"Rodriguez-Merchan EC (2021) Recent advances in surgery and its perioperative treatment in people with hemophilia. Expert Rev Hematol 14(3):271\u2013280. https:\/\/doi.org\/10.1080\/17474086.2021.1893689","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"6265_CR5","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1111\/jth.14296","volume":"16","author":"AD Shapiro","year":"2018","unstructured":"Shapiro AD, Mitchell IS, Nasr S (2018) The future of bypassing agents for hemophilia with inhibitors in the era of novel agents. J Thromb Haemost 16(12):2362\u20132374. https:\/\/doi.org\/10.1111\/jth.14296","journal-title":"J Thromb Haemost"},{"issue":"4","key":"6265_CR6","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/j.1365-2516.2010.02467.x","volume":"17","author":"A Gringeri","year":"2011","unstructured":"Gringeri A, Fischer K, Karafoulidou A, Klamroth R, Lopez-Fernandez MF, Mancuso E et al (2011) Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors. Haemophilia 17(4):630\u2013635. https:\/\/doi.org\/10.1111\/j.1365-2516.2010.02467.x","journal-title":"Haemophilia"},{"issue":"5","key":"6265_CR7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/hae.12171","volume":"19","author":"JW Hay","year":"2013","unstructured":"Hay JW, Chaugule SC, Young G (2013) Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors. Haemophilia 19(5):711\u2013719. https:\/\/doi.org\/10.1111\/hae.12171","journal-title":"Haemophilia"},{"issue":"6","key":"6265_CR8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1365-2141.2006.06087.x","volume":"133","author":"CR Hay","year":"2006","unstructured":"Hay CR, Brown S, Collins PW, Keeling DM, Liesner R (2006) The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 133(6):591\u2013605. https:\/\/doi.org\/10.1111\/j.1365-2141.2006.06087.x","journal-title":"Br J Haematol"},{"issue":"1","key":"6265_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1055\/s-0038-1646159","volume":"70","author":"IM Nilsson","year":"1993","unstructured":"Nilsson IM, Berntorp E, Freiburghaus C (1993) Treatment of patients with factor VIII and IX inhibitors. Thromb Haemost 70(1):56\u201359","journal-title":"Thromb Haemost"},{"key":"6265_CR10","doi-asserted-by":"publisher","unstructured":"Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW et al (2020) WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 26 Suppl 6:1-158. https:\/\/doi.org\/10.1111\/hae.14046","DOI":"10.1111\/hae.14046"},{"issue":"4","key":"6265_CR11","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.blre.2018.02.003","volume":"32","author":"SJ Schep","year":"2018","unstructured":"Schep SJ, Schutgens REG, Fischer K, Boes ML (2018) Review of immune tolerance induction in hemophilia A. Blood Rev 32(4):326\u2013338. https:\/\/doi.org\/10.1016\/j.blre.2018.02.003","journal-title":"Blood Rev"},{"issue":"2","key":"6265_CR12","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.clinthera.2012.01.001","volume":"34","author":"ZY Zhou","year":"2012","unstructured":"Zhou ZY, Hay JW (2012) Efficacy of bypassing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis. Clin Ther 34(2):434\u2013445. https:\/\/doi.org\/10.1016\/j.clinthera.2012.01.001","journal-title":"Clin Ther"},{"issue":"1","key":"6265_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/vox.12726","volume":"114","author":"CH Kim","year":"2019","unstructured":"Kim CH, Simmons SC, Bui CM, Jiang N, Pham HP (2019) aPCC vs. rFVIIa for the treatment of bleeding in patients with acquired haemophilia - a cost-effectiveness model. Vox Sang 114(1):63\u201372. https:\/\/doi.org\/10.1111\/vox.12726","journal-title":"Vox Sang"},{"issue":"5","key":"6265_CR14","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1055\/a-1159-4273","volume":"40","author":"HH Brackmann","year":"2020","unstructured":"Brackmann HH, Schramm W, Oldenburg J, Cano V, Turecek PL, Negrier C, Origins (2020) Development, Current challenges and future directions with activated Prothrombin Complex Concentrate for the treatment of patients with congenital haemophilia with inhibitors. Hamostaseologie 40(5):606\u2013620. https:\/\/doi.org\/10.1055\/a-1159-4273","journal-title":"Hamostaseologie"},{"issue":"6","key":"6265_CR15","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/j.1365-2516.2010.02329.x","volume":"16","author":"C Balkan","year":"2010","unstructured":"Balkan C, Karapinar D, Aydogdu S, Ozcan C, Ay Y, Akin M et al (2010) Surgery in patients with haemophilia and high responding inhibitors: Izmir experience. Haemophilia 16(6):902\u2013909. https:\/\/doi.org\/10.1111\/j.1365-2516.2010.02329.x","journal-title":"Haemophilia"},{"issue":"4","key":"6265_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3760\/cma.j.issn.0253-2727.2020.04.001","volume":"41","author":"Thrombosis","year":"2020","unstructured":"Thrombosis, Hemostasis Group CSoH, Chinese Medical Association\/Hemophilia Treatment Center Collaborative Network of C (2020) [Chinese guidelines on the treatment of hemophilia (version 2020)]. Zhonghua Xue Ye Xue Za Zhi 41(4):265\u2013271. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2020.04.001","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"6265_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/ejh.12372","volume":"76","author":"BA Laros-van Gorkom","year":"2014","unstructured":"Laros-van Gorkom BA, Falaise C, Astermark J (2014) Immunosuppressive agents in the treatment of inhibitors in congenital haemophilia A and B\u2013a systematic literature review. Eur J Haematol Suppl 76:26\u201338. https:\/\/doi.org\/10.1111\/ejh.12372","journal-title":"Eur J Haematol Suppl"},{"issue":"Suppl 2","key":"6265_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1365-2516.2004.00938.x","volume":"10","author":"M Quintana-Molina","year":"2004","unstructured":"Quintana-Molina M, Martinez-Bahamonde F, Gonzalez-Garcia E, Romero-Garrido J, Villar-Camacho A, Jimenez-Yuste V et al (2004) Surgery in haemophilic patients with inhibitor: 20 years of experience. Haemophilia 10(Suppl 2):30\u201340. https:\/\/doi.org\/10.1111\/j.1365-2516.2004.00938.x","journal-title":"Haemophilia"},{"issue":"5 Suppl","key":"6265_CR19","first-page":"s126","volume":"22","author":"SL Chen","year":"2016","unstructured":"Chen SL (2016) Economic costs of hemophilia and the impact of prophylactic treatment on patient management. Am J Manag Care 22(5 Suppl):s126\u2013s133","journal-title":"Am J Manag Care"},{"issue":"9","key":"6265_CR20","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3760\/cma.j.issn.0253-2727.2020.09.013","volume":"41","author":"PP Xu","year":"2020","unstructured":"Xu PP, Zhou H, Zhang P, Wang JQ, Liu L, Li C et al (2020) [Perioperative application of recombinant human coagulation factor or gery in haith prothrombin complex in two hemophilia A patients with high titer inhibitor]. Zhonghua Xue Ye Xue Za Zhi 41(9):773\u2013775. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2020.09.013","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"3","key":"6265_CR21","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1365-2516.2007.01451.x","volume":"13","author":"J Schneiderman","year":"2007","unstructured":"Schneiderman J, Rubin E, Nugent DJ, Young G (2007) Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 13(3):244\u2013248. https:\/\/doi.org\/10.1111\/j.1365-2516.2007.01451.x","journal-title":"Haemophilia"},{"issue":"1","key":"6265_CR22","first-page":"60","volume":"88","author":"NS Key","year":"2002","unstructured":"Key NS, Christie B, Henderson N, Nelsestuen GL (2002) Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy. Thromb Haemost 88(1):60\u201365","journal-title":"Thromb Haemost"},{"issue":"4","key":"6265_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1365-2516.2004.00912.x","volume":"10","author":"J Schneiderman","year":"2004","unstructured":"Schneiderman J, Nugent DJ, Young G (2004) Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia 10(4):347\u2013351. https:\/\/doi.org\/10.1111\/j.1365-2516.2004.00912.x","journal-title":"Haemophilia"},{"issue":"5","key":"6265_CR24","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/j.1365-2516.2007.01523.x","volume":"13","author":"EH Kraut","year":"2007","unstructured":"Kraut EH, Aledort LM, Arkin S, Stine KC, Wong WY (2007) Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review. Haemophilia 13(5):508\u2013517. https:\/\/doi.org\/10.1111\/j.1365-2516.2007.01523.x","journal-title":"Haemophilia"},{"issue":"17","key":"6265_CR25","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1182\/bloodadvances.2017008409","volume":"1","author":"CD Seaman","year":"2017","unstructured":"Seaman CD, Ragni MV (2017) Sequential bypassing agents during major orthopedic surgery: a new approach to hemostasis. Blood Adv 1(17):1309\u20131311. https:\/\/doi.org\/10.1182\/bloodadvances.2017008409","journal-title":"Blood Adv"},{"key":"6265_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05287-2","author":"M Shima","year":"2023","unstructured":"Shima M (2023) Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven(R), in the treatment of haemophilia and rare bleeding disorders. Ann Hematol. https:\/\/doi.org\/10.1007\/s00277-023-05287-2","journal-title":"Ann Hematol"},{"issue":"5","key":"6265_CR27","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3760\/cma.j.issn.0253-2727.2017.05.002","volume":"38","author":"Thrombosis","year":"2017","unstructured":"Thrombosis, Hemostasis Group HSoCMA, Hemophilia Treatment Center Collaborative Network of C (2017) [Consensus of Chinese expert on the diagnosis and treatment of hemophilia (version 2017)]. Zhonghua Xue Ye Xue Za Zhi 38(5):364\u2013370. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2017.05.002","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"1","key":"6265_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/hae.12518","volume":"21","author":"E Santagostino","year":"2015","unstructured":"Santagostino E, Lentz SR, Misgav M, Brand B, Chowdary P, Savic A et al (2015) Safety and efficacy of turoctocog alfa (NovoEight(R)) during surgery in patients with haemophilia A: results from the multinational guardian clinical trials. Haemophilia 21(1):34\u201340. https:\/\/doi.org\/10.1111\/hae.12518","journal-title":"Haemophilia"},{"issue":"11","key":"6265_CR29","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1111\/jth.12672","volume":"12","author":"VS Blanchette","year":"2014","unstructured":"Blanchette VS, Key NS, Ljung LR, Manconco B, Chowdary P, Savic A et al (2014) Safety and efficacy of turoctocog alfa (NovoEight(R)) during surgery in pH. J Thromb Haemost 12(11):1935\u20131939. https:\/\/doi.org\/10.1111\/jth.12672","journal-title":"J Thromb Haemost"},{"issue":"7","key":"6265_CR30","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/MBC.0b013e32832c8803","volume":"20","author":"LK Amby","year":"2009","unstructured":"Amby LK, Seremetis S, Obergfell A, Bjerre J (2009) Challenges of defining reliable clinical surrogate end points in haemophilia trials: a critical review. Blood Coagul Fibrinolysis 20(7):488\u2013493. https:\/\/doi.org\/10.1097\/MBC.0b013e32832c8803","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"4","key":"6265_CR31","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/bjh.15209","volume":"181","author":"K Nogami","year":"2018","unstructured":"Nogami K, Matsumoto T, Yada K, Ogiwara K, Furukawa S, Shida Y et al (2018) Factor (F)VIII\/VIIa enhances global haemostatic function in the co-presence of bypassing agents and FVIII among patients with haemophilia A with inhibitor. Br J Haematol 181(4):528\u2013536. https:\/\/doi.org\/10.1111\/bjh.15209","journal-title":"Br J Haematol"},{"issue":"2","key":"6265_CR32","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1055\/s-0040-1710032","volume":"4","author":"Y Zong","year":"2020","unstructured":"Zong Y, Antovic A, Soutari NMH, Antovic J, Pruner I (2020) Synergistic effect of bypassing agents and sequence identical analogue of Emicizumab and Fibrin clot structure in the in vitro model of Hemophilia A. TH Open 4(2):e94\u2013e103. https:\/\/doi.org\/10.1055\/s-0040-1710032","journal-title":"TH Open"},{"issue":"1","key":"6265_CR33","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/hae.14213","volume":"27","author":"H Kizilocak","year":"2021","unstructured":"Kizilocak H, Marquez-Casas E, Phei Wee C, Malvar J, Carmona R, Young G (2021) Comparison of bypassing agents in patients on emicizumab using global hemostasis assays. Haemophilia 27(1):164\u2013172. https:\/\/doi.org\/10.1111\/hae.14213","journal-title":"Haemophilia"},{"issue":"5","key":"6265_CR34","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/j.1365-2516.2009.02038.x","volume":"15","author":"PO Bonnet","year":"2009","unstructured":"Bonnet PO, Yoon BS, Wong WY, Boswell K, Ewenstein BM (2009) Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries. Haemophilia 15(5):1083\u20131089. https:\/\/doi.org\/10.1111\/j.1365-2516.2009.02038.x","journal-title":"Haemophilia"},{"issue":"2","key":"6265_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1365-2141.2011.08854.x","volume":"155","author":"J Ingerslev","year":"2011","unstructured":"Ingerslev J, Sorensen B (2011) Parallel use of by-passing agents in haemophilia with inhibitors: a critical review. Br J Haematol 155(2):256\u2013262. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08854.x","journal-title":"Br J Haematol"},{"issue":"4","key":"6265_CR36","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/hae.12365","volume":"20","author":"JJ van Veen","year":"2014","unstructured":"van Veen JJ, Maclean RM, Hampton KK, Hamer A, Makris M (2014) Major surgery in severe haemophilia A with inhibitors using a recombinant factor VIIa and activated prothrombin complex concentrate hybrid regimen. Haemophilia 20(4):587\u2013592. https:\/\/doi.org\/10.1111\/hae.12365","journal-title":"Haemophilia"},{"issue":"2","key":"6265_CR37","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/j.1365-2516.2007.01635.x","volume":"14","author":"M Economou","year":"2008","unstructured":"Economou M, Teli A, Tzantzaroudi A, Tsatra I, Zavitsanakis A, Athanassiou-Metaxa M (2008) Sequential therapy with activated prothrombin complex concentrate (FEIBA) and recombinant factor VIIa in a patient with severe haemophilia A, inhibitor presence and refractory bleeding. Haemophilia 14(2):390\u2013391. https:\/\/doi.org\/10.1111\/j.1365-2516.2007.01635.x","journal-title":"Haemophilia"},{"issue":"3","key":"6265_CR38","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/j.1538-7836.2007.02313.x","volume":"5","author":"CH Toh","year":"2007","unstructured":"Toh CH, Hoots WK, ISTH SSCoDICot (2007) The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on thrombosis and haemostasis: a 5-year overview. J Thromb Haemost 5(3):604\u2013606. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02313.x","journal-title":"J Thromb Haemost"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06265-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06265-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06265-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:10:19Z","timestamp":1745575819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06265-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6265"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06265-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"25 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was was established according to the ethical guidelines of the Helsinki Declaration and was approved by the Medical Ethics Committee of Henan Cancer Hospital (approval number: 2023-377-002). Written informed consent was obtained from individual participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}